Immune cell infusion plus transplant for tough leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new two-step approach for people with hard-to-treat leukemia. First, you get chemotherapy plus an infusion of special immune cells from a partially matched donor, then a stem cell transplant. The goal is to see if this is safe and helps the leukemia go away.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 15 years old or older.
- Your leukemia has come back or not gotten better with standard treatment.
- You have a donor (at least 18 years old) who is a partial blood type match and willing to donate stem cells (and possibly a second donor for a later transplant).
- Your liver and kidney function tests are within safe limits, and your heart pumps well (LVEF above 50%).
- You are not pregnant, nursing, or unwilling to use birth control, and you don't have serious infections, heart disease, or other life-threatening conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of medicines to prevent graft-versus-host disease (GVHD) in patients with leukemia or myelodysplastic syndromes receiving a stem cell transplant from a half-matched donor. It aims to see if using less anti-thymocyte globulin (ATG) plus a simpler post-transplant cyclophosphamide (PTCy) regimen works as well as standard care with fewer side effects.
This Phase 2 study looks at a specific type of stem cell transplant that uses donor stem cells with immune cells removed, to treat certain high-risk leukemias and lymphomas. It aims to reduce relapse risk and improve outcomes in people who may need a transplant but have specific disease features.
This Phase 2 trial tests whether a specific stem cell transplant method (from a related “half-matched” donor) plus conditioning chemo and radiation can improve outcomes for several blood cancers. It may help people whose cancer is in remission but still considered high risk, or those who have had limited response after prior treatment.
This Phase 1 trial tests a special bone marrow transplant using a related “half-matched” donor (haploidentical), without a specific immune-suppressing medicine (“IS-free”). It’s for adults with certain high-risk AML or MDS to see if this approach can improve control of the disease while tracking safety.
This trial tests a special transplant approach for people with high-risk acute leukemia. It uses a stronger dose of radiation before transplant, followed by an infusion of immune cells (regulatory and conventional T cells) to help the transplant work better and fight the leukemia.
This trial tests whether removing certain immune cells (T cells) from the donor transplant can lower the risk of chronic graft-versus-host disease (long-term immune attack after transplant) in children and young adults with blood cancers. If you qualify, it may help improve transplant outcomes while tracking safety and side effects.
Hear when a new Refractory Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.